Cargando…
The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study
While the COVID-19 pandemic disrupted healthcare delivery everywhere, persons with carceral system involvement and opioid use disorder (OUD) were disproportionately impacted and vulnerable to severe COVID-associated illness. Carceral settings and community treatment programs (CTPs) rapidly developed...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760540/ https://www.ncbi.nlm.nih.gov/pubmed/36529829 http://dx.doi.org/10.1186/s40352-022-00199-1 |
_version_ | 1784852496182673408 |
---|---|
author | Saunders, Elizabeth C. Satcher, Milan F. Monico, Laura B. McDonald, Ryan D. Springer, Sandra A. Farabee, David Gryczynski, Jan Nyaku, Amesika Reeves, Donald Kunkel, Lynn E. Schultheis, Alysse M. Schwartz, Robert P. Lee, Joshua D. Marsch, Lisa A. Waddell, Elizabeth Needham |
author_facet | Saunders, Elizabeth C. Satcher, Milan F. Monico, Laura B. McDonald, Ryan D. Springer, Sandra A. Farabee, David Gryczynski, Jan Nyaku, Amesika Reeves, Donald Kunkel, Lynn E. Schultheis, Alysse M. Schwartz, Robert P. Lee, Joshua D. Marsch, Lisa A. Waddell, Elizabeth Needham |
author_sort | Saunders, Elizabeth C. |
collection | PubMed |
description | While the COVID-19 pandemic disrupted healthcare delivery everywhere, persons with carceral system involvement and opioid use disorder (OUD) were disproportionately impacted and vulnerable to severe COVID-associated illness. Carceral settings and community treatment programs (CTPs) rapidly developed protocols to sustain healthcare delivery while reducing risk of COVID-19 transmission. This survey study assessed changes to OUD treatment, telemedicine use, and re-entry support services among carceral and CTPs participating in the National Institute on Drug Abuse (NIDA)-funded study, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in Criminal Justice System-Involved Adults (EXIT-CJS) study. In December 2020, carceral sites (n = 6; median pre-COVID 2020 monthly census = 3468 people) and CTPs (n = 7; median pre-COVID 2020 monthly census = 550 patients) participating in EXIT-CJS completed a cross-sectional web-based survey. The survey assessed changes pre- (January–March 2020) and post- (April–September 2020) COVID-19 in OUD treatment, telemedicine use, re-entry supports and referral practices. Compared to January–March 2020, half of carceral sites (n = 3) increased the total number of persons initiating medication for opioid use disorder (MOUD) from April–September 2020, while a third (n = 2) decreased the number of persons initiated. Most CTPs (n = 4) reported a decrease in the number of new admissions from April–September 2020, with two programs stopping or pausing MOUD programs due to COVID-19. All carceral sites with pre-COVID telemedicine use (n = 5) increased or maintained telemedicine use, and all CTPs providing MOUD (n = 6) increased telemedicine use. While expansion of telemedicine services supported MOUD service delivery, the majority of sites experienced challenges providing community support post-release, including referrals to housing, employment, and transportation services. During the COVID-19 pandemic, this small sample of carceral and CTP sites innovated to continue delivery of treatment for OUD. Expansion of telemedicine services was critical to support MOUD service delivery. Despite these innovations, sites experienced challenges providing reintegration supports for persons in the community. Pre-COVID strategies for identifying and engaging individuals while incarcerated may be less effective since the pandemic. In addition to expanding research on the most effective telemedicine practices for carceral settings, research exploring strategies to expand housing and employment support during reintegration are critical. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40352-022-00199-1. |
format | Online Article Text |
id | pubmed-9760540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-97605402022-12-19 The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study Saunders, Elizabeth C. Satcher, Milan F. Monico, Laura B. McDonald, Ryan D. Springer, Sandra A. Farabee, David Gryczynski, Jan Nyaku, Amesika Reeves, Donald Kunkel, Lynn E. Schultheis, Alysse M. Schwartz, Robert P. Lee, Joshua D. Marsch, Lisa A. Waddell, Elizabeth Needham Health Justice Short Report While the COVID-19 pandemic disrupted healthcare delivery everywhere, persons with carceral system involvement and opioid use disorder (OUD) were disproportionately impacted and vulnerable to severe COVID-associated illness. Carceral settings and community treatment programs (CTPs) rapidly developed protocols to sustain healthcare delivery while reducing risk of COVID-19 transmission. This survey study assessed changes to OUD treatment, telemedicine use, and re-entry support services among carceral and CTPs participating in the National Institute on Drug Abuse (NIDA)-funded study, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in Criminal Justice System-Involved Adults (EXIT-CJS) study. In December 2020, carceral sites (n = 6; median pre-COVID 2020 monthly census = 3468 people) and CTPs (n = 7; median pre-COVID 2020 monthly census = 550 patients) participating in EXIT-CJS completed a cross-sectional web-based survey. The survey assessed changes pre- (January–March 2020) and post- (April–September 2020) COVID-19 in OUD treatment, telemedicine use, re-entry supports and referral practices. Compared to January–March 2020, half of carceral sites (n = 3) increased the total number of persons initiating medication for opioid use disorder (MOUD) from April–September 2020, while a third (n = 2) decreased the number of persons initiated. Most CTPs (n = 4) reported a decrease in the number of new admissions from April–September 2020, with two programs stopping or pausing MOUD programs due to COVID-19. All carceral sites with pre-COVID telemedicine use (n = 5) increased or maintained telemedicine use, and all CTPs providing MOUD (n = 6) increased telemedicine use. While expansion of telemedicine services supported MOUD service delivery, the majority of sites experienced challenges providing community support post-release, including referrals to housing, employment, and transportation services. During the COVID-19 pandemic, this small sample of carceral and CTP sites innovated to continue delivery of treatment for OUD. Expansion of telemedicine services was critical to support MOUD service delivery. Despite these innovations, sites experienced challenges providing reintegration supports for persons in the community. Pre-COVID strategies for identifying and engaging individuals while incarcerated may be less effective since the pandemic. In addition to expanding research on the most effective telemedicine practices for carceral settings, research exploring strategies to expand housing and employment support during reintegration are critical. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40352-022-00199-1. Springer Berlin Heidelberg 2022-12-19 /pmc/articles/PMC9760540/ /pubmed/36529829 http://dx.doi.org/10.1186/s40352-022-00199-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Short Report Saunders, Elizabeth C. Satcher, Milan F. Monico, Laura B. McDonald, Ryan D. Springer, Sandra A. Farabee, David Gryczynski, Jan Nyaku, Amesika Reeves, Donald Kunkel, Lynn E. Schultheis, Alysse M. Schwartz, Robert P. Lee, Joshua D. Marsch, Lisa A. Waddell, Elizabeth Needham The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study |
title | The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study |
title_full | The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study |
title_fullStr | The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study |
title_full_unstemmed | The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study |
title_short | The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study |
title_sort | impact of covid-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760540/ https://www.ncbi.nlm.nih.gov/pubmed/36529829 http://dx.doi.org/10.1186/s40352-022-00199-1 |
work_keys_str_mv | AT saunderselizabethc theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT satchermilanf theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT monicolaurab theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT mcdonaldryand theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT springersandraa theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT farabeedavid theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT gryczynskijan theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT nyakuamesika theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT reevesdonald theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT kunkellynne theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT schultheisalyssem theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT schwartzrobertp theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT leejoshuad theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT marschlisaa theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT waddellelizabethneedham theimpactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT saunderselizabethc impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT satchermilanf impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT monicolaurab impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT mcdonaldryand impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT springersandraa impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT farabeedavid impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT gryczynskijan impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT nyakuamesika impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT reevesdonald impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT kunkellynne impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT schultheisalyssem impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT schwartzrobertp impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT leejoshuad impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT marschlisaa impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy AT waddellelizabethneedham impactofcovid19onthetreatmentofopioidusedisorderincarceralfacilitiesacrosssectionalstudy |